Kuehn Law Encourages Investors of Fractyl Health, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Fractyl Health, Inc. to Contact Law Firm
PR Newswire
NEW YORK, Sept. 23, 2026
NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Fractyl Health, Inc. (NASDAQ: GUTS) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Fractyl Health misrepresented or failed to disclose (i) Revita, an outpatient therapy designed to modify duodenal dysfunction, was less effective than the Company had led investors to believe, and/or operational issues at one or more of its efficacy clinical study sites compromised the integrity of its efficacy results; and (ii) accordingly, Revita's clinical, regulatory, and commercial prospects were overstated, as was its efficacy study's ability to assess Revita's efficacy.
If you currently own GUTS and purchased prior to January 13, 2025 please contact Sophia Anne Silayan, by email at sophiaanne@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
SOURCE Kuehn Law, PLLC
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
These Overvalued Stocks Have Plenty of Room to Fall
United States